浙商证券：脑机接口触达更广阔市场 国内政策与产业窗口期共振

Core Insights - Neuralink's first product, Telepathy, is expected to enter mass production this year, with over 10,000 applicants for trials, and the company is currently valued at over $9 billion [1][2] - The vision of Neuralink is to enhance communication bandwidth and efficiency by connecting the human brain with AI, potentially allowing ordinary people to interact with AI and control complex machinery through brain-machine interfaces [2] - The Chinese government's ten-year brain plan (2021-2030) is entering a critical implementation phase, positioning brain-machine interfaces as a future industry with significant policy support [3] Group 1: Product Development and Market Potential - Telepathy focuses on severe cases where brain function is normal but communication pathways are disrupted, such as spinal cord injuries and ALS patients [1] - Key conditions for mass production include performance enhancement of the N1 device, improved surgical safety, and reduced costs: the number of electrodes is expected to increase from 1,000 to 3,000 by 2026, and the cost of the needle kit is projected to drop from $350 to $15 [1] - The anticipated advancements in surgical techniques will reduce invasiveness and infection risks, allowing for smoother post-operative operations [1] Group 2: Policy and Industry Landscape - The Chinese government has issued implementation opinions to promote innovation in the brain-machine interface industry, aiming for significant technological breakthroughs by 2027 and enhanced innovation capabilities by 2030 [3] - Technical standards for brain-machine interfaces are being developed, with a roadmap set for completion by 2025, and a standardization committee established by the Ministry of Industry and Information Technology [3] Group 3: Clinical Advancements - The number of registered clinical studies for invasive brain-machine interfaces in China has significantly increased since 2024, with notable advancements from institutions like the Chinese Academy of Sciences [4] - Semi-invasive technologies are progressing rapidly, with successful implant surgeries conducted on numerous patients [4] Group 4: Integration with AI and Technology - The integration of brain-machine interfaces with large models is expected to enhance generalization capabilities and accelerate application deployment, transitioning from specialized models to a more universal intelligent foundation [5] - The combination of brain-machine interfaces with embodied intelligence aims to enhance human-machine interaction, particularly in rehabilitation and robotic control applications [6] Group 5: Market Players - Key players in the secondary market are focusing on non-invasive technology, with medical companies specializing in rehabilitation and tech firms advancing in algorithms and consumer-grade brain-machine products [7] - Notable medical service and device companies include Aipeng Medical, Xiangyu Medical, and Sanbo Brain Science, while tech firms include Entropy Technology and Yanshan Technology [7]